About: Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3
Creator	Kim, Myungshin Kim, Yonggoo Jekarl, Dong Lee, Jeong Lee, \| Seon, \| Woo, Hee Woon, \|
Source	Medline; PMC
abstract	BACKGROUND: The revised definition of sepsis is life‐threatening organ dysfunction caused by a dysregulated host response to infection (SEPSIS‐3). The objective of this study was to evaluate procalcitonin (PCT) for the diagnosis and prognosis of sepsis using SEPSIS‐3. METHODS: We enrolled 248 patients, who were admitted to the emergency department with suspected bacterial infection from June 2016 to February 2017. Definite bacterial infection was defined by proven culture results, and probable bacterial infection was based on diagnostic modalities other than culture. The sequential organ failure assessment (SOFA) score of 2 points or more from the baseline was diagnosed as sepsis. PCT was measured by the AFIAS‐6 immunoassay system (Boditech Med Inc.) using whole blood. White blood cell (WBC), C‐reactive protein (CRP), and erythrocyte sedimentation rate (ERS) were evaluated. RESULTS: The final diagnosis was sepsis in 185 patients with infection of respiratory and genitourinary tract constituted 84.6%. The area under the receiver operating characteristic curve (AUROC) with 95% confidence interval (CI) was as follows: PCT, 0.682 (0.589‐0.765); CRP, 0.583 (0.487‐0.673); ESR, 0.540 (0.515‐0.699); and WBC, 0.611 (0.455‐0.633), respectively. In multivariate analysis, age, SOFA, and PCT (log scale) predicted non‐survivors with an odds ratio with 95% confidence interval of 1.055 (1.008‐1.105), 1.303 (1.142‐1.486), and 2.004 (1.240‐3.238), respectively. Among sepsis group, initial PCT was increased in non‐survivor (23.2 ng/dL) compared to survivor group (8.1 ng/dL) with statistical significance (P = .005). CONCLUSIONS: PCT could support and predict the unfavorable prognosis of sepsis based on SEPSIS‐3, whereas diagnostic potential of PCT requires further evaluations.
has issue date	2019-08-16(xsd:dateTime)
bibo:doi	10.1002/jcla.22996
bibo:pmid	31420921
has license	cc-by
sha1sum (hex)	74d95e321596279f3e8fcf1ad1f04508f48552e2
schema:url	https://doi.org/10.1002/jcla.22996
resource representing a document's title	Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3
has PubMed Central identifier	PMC6868407
has PubMed identifier	31420921
schema:publication	J Clin Lab Anal
resource representing a document's body	covid:74d95e321596279f3e8fcf1ad1f04508f48552e2#body_text
is schema:about of	named entity 'prognosis' named entity 'caused' named entity 'PROCALCITONIN' named entity 'DEFINITION' named entity 'DIAGNOSIS' named entity 'LIFE' named entity 'SEPSIS' named entity 'STUDY' named entity 'DYSREGULATED HOST RESPONSE' named entity 'ORGAN' named entity 'REVISED' named entity 'OBJECTIVE' named entity 'EVALUATE' named entity 'RESPONSE TO' named entity 'CAUSED BY' named entity 'SEPSIS' named entity 'PROGNOSTIC MARKER' named entity 'PROCALCITONIN' named entity 'BASED' named entity 'DYSFUNCTION' named entity 'PROGNOSIS' named entity 'INFECTION' named entity 'USING' covid:arg/74d95e321596279f3e8fcf1ad1f04508f48552e2 named entity 'SEPSIS' named entity 'infection' named entity 'coagulation' named entity 'endocrine' named entity 'alveolar' named entity 'sensitivity and specificity' named entity 'treatment of patients' named entity 'interleukins' named entity 'sepsis' named entity 'genitourinary tract' named entity 'C-reactive protein' named entity 'ng/mL' named entity 'SOFA score' named entity 'sepsis' named entity 'diagnostic criteria' named entity 'institutional review board' named entity 'sepsis' named entity 'incubation' named entity 'bilirubin' named entity 'bilirubin' named entity 'CRP' named entity 'blood cultures' named entity 'microbial' named entity 'prognosis' named entity 'biomarkers' named entity 'clinical setting' named entity 'respiratory tract' named entity 'infection' named entity 'organ dysfunction' named entity 'SOFA score' named entity 'creatinine' named entity 'biomarkers' named entity 'ESR' named entity 'SIRS' named entity 'SIRS' named entity 'sepsis' named entity 'SOFA score' named entity 'sepsis' named entity 'Cytokines' named entity 'sepsis' named entity 'bacteria' named entity 'severe sepsis' named entity 'Escherichia coli' named entity 'severe sepsis' named entity 'WBC' named entity 'Surviving Sepsis Campaign' named entity 'biomarkers' named entity 'sepsis' named entity 'SIRS' named entity 'multivariate analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software